Andrew Ferguson is responsible for leading the computational, machine learning, and software development efforts at Evozyne. Andrew is an Associate Professor at the Pritzker School of Molecular Engineering at the University of Chicago. His research uses theory, simulation, and machine learning to understand and design self-assembling materials, macromolecular folding, and antiviral therapies. He holds a PhD in chemical and biological engineering from Princeton University, and was a Postdoctoral Fellow of the Ragon Institute of MGH, MIT, and Harvard.
Advisors
Gary Krishnan is a seasoned biopharma leader with more than 26 years of experience spanning discovery, translational science, and R&D leadership. He spent the majority of his career at Eli Lilly, where he held senior executive roles including Chief Scientific Officer for Aging, Musculoskeletal, and Urology Research and Global Head of Translational Research for Immunology. Krishnan has advanced more than a dozen assets into clinical development, contributed to four blockbuster medicines, and led the discovery of one of the first therapies for hospitalized COVID-19 patients. He holds a PhD in biochemistry and biophysics from Texas A&M University and completed postdoctoral training at Baylor College of Medicine.